ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1399

Transitioning Lupus Patients from Pediatric to Adult Rheumatology

Joyce Hui-Yuen1, Ashlea Cook2, Lisa F. Imundo3, Amy Starr2, Andrew Eichenfield4 and Anca D. Askanase5, 1North Shore-Long Island Jewish Health System, Lake Success, NY, 2Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 3Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, 4Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, 5Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: pediatrics, Quality of care and systemic lupus erythematosus (SLE), Transition

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pediatric rheumatologists have successfully improved the life expectancy and quality of life of children with systemic lupus (cSLE). cSLE has higher morbidity and mortality than adult SLE; the young adult with SLE may have severe system involvement at the time of transition. The consequences of poor transition in this at-risk population are loss of continuity in care and medication regimen, as well as worse disease activity and damage. As data are scarce on successful transition of cSLE patients to adult care, we conducted a pilot study to better understand how to facilitate this transition.

Methods: Patients with cSLE ≥14 years old who fulfilled ACR SLE criteria were evaluated using a 29-item Transition Readiness Questionnaire (SLE-TRQ) adapted from transitioning questionnaires in other chronic disease. It included medical and life skills, medical knowledge and independent living, and feelings/stress about transition. A protocol based on the American Academy of Pediatrics guidelines for successful transition was implemented for patients ≥18 years old. All patients met with the adult rheumatologist in the pediatric clinic and were accompanied to their first adult clinic visit by the Pediatric Rheumatology nurse. Successful transition was defined as ≥ 3 visits with the adult rheumatologist. All successfully transitioned patients were asked to complete a Satisfaction Questionnaire (SQ).

Results: 40 patients with a mean age of 18.4 years completed the SLE-TRQ. The mean disease duration was 5.25 years; 75% were female; 45% Hispanic, 40% African American, 7% Caucasian. There were 93% who had major organ involvement, 19 (48%) renal disease, 8 (20%) neuropsychiatric lupus, 3 (10%) abnormal pulmonary function tests and 2 (5%) anti-phospholipid syndrome. Eleven patients were on prednisone, median dose 20 mg/day at the time of enrollment. Over 50% were non-adherent at least on one occasion with medications and appointments. On the SLE-TRQ, 27 patients reported good medical and life skills, and 14 had good knowledge. However, 16/40 admitted to uneasiness/unreadiness for transition. The mean scores were: skills- 1.39, knowledge- 2.4 and feelings about transition- 2.3, where scores of 4-5 identify patients that are not ready, 2-3 patients in preparation and 0-1 ready for transition. Of the 20 patients scheduled to transition, 12 were successfully transferred, and 8 remain under pediatric care, scheduled to transition at a later date. The mean SLEDAI at the last pediatric visit was 5.6 and at the third adult visit 5.25. Three patients were on prednisone (mean dose 13.8 mg/day). Nine patients completed the SQ, reporting satisfaction with the transition process.

Conclusion: This is the first study evaluating self-reported pre-transition readiness in cSLE and satisfaction with the transition process. Patients had good medical knowledge and independent living skills but were not psychologically ready to transition. We were able to successfully transition 60% of the patients with good satisfaction. However, 40% were not transitioned, suggesting adolescents with cSLE and major organ involvement need additional support in the transition to adult rheumatology.


Disclosure: J. Hui-Yuen, None; A. Cook, None; L. F. Imundo, None; A. Starr, None; A. Eichenfield, None; A. D. Askanase, None.

To cite this abstract in AMA style:

Hui-Yuen J, Cook A, Imundo LF, Starr A, Eichenfield A, Askanase AD. Transitioning Lupus Patients from Pediatric to Adult Rheumatology [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/transitioning-lupus-patients-from-pediatric-to-adult-rheumatology/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transitioning-lupus-patients-from-pediatric-to-adult-rheumatology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology